Report Materials
For fiscal years 2004 and 2005, West Virginia claimed $286,000 in Medicaid reimbursement for a duplicate prior period adjustment and for prescription drugs that were ineligible for reimbursement. The Medicaid drug rebate program generally pays for covered outpatient drugs if their manufacturers have rebate agreements with Centers for Medicare & Medicaid Services (CMS) and pay rebates to the States. Under the drug rebate program, CMS provides the States with a quarterly Medicaid drug tape, which the States use to verify coverage of the drugs for which they claim reimbursement.
An additional $2.1 million represented expenditures for drug products that were not listed on the quarterly drug tapes. Because the Department of Health and Human Resources (the State agency) did not verify whether these drugs were eligible for coverage, these expenditures may not have been allowable. We identified no other errors for the remainder of the $808 million ($615 million Federal share) that the State claimed.
We recommended that the State (1) refund $286,000 to the Federal Government for a duplicate prior period adjustment and for drug expenditures that were not eligible for Medicaid coverage, (2) work with CMS to resolve $2.1 million in payments for drugs that were not listed on the quarterly drug tapes and that may not have been eligible for Medicaid coverage, and (3) strengthen internal controls to ensure that claimed Medicaid drug expenditures comply with Federal requirements. The State agreed with our recommendations .Notice
This report may be subject to section 5274 of the National Defense Authorization Act Fiscal Year 2023, 117 Pub. L. 263.